Drug Profile
Sustained release therapeutic - DURECT/Santen Pharmaceutical
Latest Information Update: 13 May 2020
Price :
$50
*
At a glance
- Originator Santen Pharmaceutical
- Developer DURECT Corporation; Santen Pharmaceutical
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 16 Dec 2014 Preclinical trials in Eye disorders in Japan (Ophthalmic)